International Western Radiation Therapy Guidelines Applicability in Low- and Middle-Income Countries for Cervical Cancer Management: A Comparative Survey Example from South and North Border of the Mediterranean Area Countries Authors: Hamza Samlali, Cyrus Chargari, Isabelle Flandin, Najlaa Assaid, Abdelkader Acharki, Abdelatif Benider, Nadia Benchekroun, Issam Layla, Hassan Jouhadi, Souha Sahraoui, Redouane Samlali, Yazid Belkacemi, AROME (Association of Radiotherapy and Oncology of the Mediterranean Area; www.aromecancer.org) Published: 2026 ABSTRACT PurposeThis comparative study evaluates the applicability of international radiation therapy guidelines in the management of cervical cancer between high-income countries and low- and middle-income countries (LMICs). Understanding differences in clinical practice is essential to identify gaps and areas for improvement in LMICs.Methods and MaterialsA cross-sectional survey was conducted using an online questionnaire distributed among specialists involved in cervical cancer care from France (high-income countries) and Morocco (LMIC). Responses from 77 participants (45 from Morocco, 32 from France), predominantly females aged 40 to 49 years, were analyzed to assess diagnostic, therapeutic, and imaging practices.ResultsSignificant differences were observed between the 2 countries. Human papillomavirus vaccination coverage was low, with 86.8% of respondents reporting that their patients were not vaccinated. Magnetic resonance imaging use before brachytherapy (BCT) was more frequent in France (90%) compared with Morocco (25%). Positron emission tomography-computed tomography for lumbar-aortic staging was widely used in France (97%) versus 59% in Morocco.Therapeutic approaches for the International Federation of Gynecology and Obstetrics stages IB1 and IB2 varied, with Morocco favoring preoperative BCT more often (34% vs 16%). Image-guided brachytherapy was systematically used in both countries, but combined intracavitary and interstitial applications were more frequent in France (64% vs 9%). In Morocco, dosimetric outcomes were generally satisfactory, with a D90 dose to the high-risk clinical target volume >85 Gy achieved in 78% of cases, supported by volumetric modulated arc therapy and computed tomography-based planning.ConclusionsOur findings highlight the ability of Moroccan teams to adapt their practice to most Western guidelines for cervical cancer, despite resource limitations. However, there is a crucial need for infrastructure development and continuous training to support long-term harmonization of clinical practice. Significant efforts are also required to improve human papillomavirus vaccination coverage, enhance access to magnetic resonance imaging and positron emission tomography-computed tomography, and optimize the use of high-dose-rate BCT. Introduction Cervical cancer represents a major worldwide public health challenge for women. Its incidence varies significantly across regions, influenced by human papillomavirus (HPV) prevalence, as well as environmental and socioeconomic determinants.1 Persistent infection with HPV is considered the primary cause of cervical cancer.2 HPV accounts for 90% to 100% of cervical cancer cases, particularly in women aged under 35 years.3 Beyond biological factors, additional epidemiological risk factors affecting cervical cancer incidence include smoking, oral contraceptive use, early sexual debut, a high number of sexual partners, history of sexually transmitted infections, and certain chronic immunosuppressive conditions.4 According to the World Health Organization (WHO), cervical cancer remains the fourth most common cancer in women worldwide, with approximately 660,000 new cases and 350,000 deaths in 2022, of which nearly 94% occur in low- and middle-income countries (LMICs).5 This reflects major inequities in access to HPV vaccination, screening, and timely treatment services. In response, the WHO has launched a global elimination strategy based on the “90-70-90” targets (90% HPV vaccination, 70% screening, and 90% access to appropriate treatment), aiming to eliminate cervical cancer as a public health problem.5 France is characterized by a universal health coverage system with a predominantly publicly funded health care model, ensuring nearly full population coverage through statutory health insurance and complementary private insurance schemes.6 The system is supported by a high density of health care providers and well-established hospital and outpatient infrastructures, allowing widespread access to advanced diagnostic and radiation therapy technologies, including magnetic resonance imaging (MRI)-guided and image-guided brachytherapy systems.7 In contrast, Morocco operates under a mixed public–private health care system undergoing transition toward universal health coverage, with expanding insurance schemes but persistent disparities in resource allocation.8,9 The country remains characterized by a lower density of specialized oncology centers, unequal geographic distribution of care, and limited access to advanced imaging and radiation therapy infrastructure, particularly outside major urban areas.8,9 Cervical cancer burden and outcomes are strongly influenced by health system–related factors, including access to screening, vaccination, imaging, and treatment infrastructure, which remain limited in many LMICs.10 In these settings, structural constraints such as insufficient radiation therapy facilities, limited access to advanced imaging modalities, and workforce shortages significantly impact the implementation of international guidelines.10 In Morocco, cervical cancer is frequently diagnosed at locally advanced stages, reflecting limited access to organized screening and early detection programs.11 In addition, delays in access to diagnosis and treatment, as well as incomplete adherence to recommended therapeutic pathways, remain major challenges in cervical cancer management.12 Morocco represents a relevant intermediate-resource setting, having implemented national cancer control strategies while still facing disparities in access to advanced oncologic care.12 These characteristics are shared by many LMICs, supporting their relevance as a model for evaluating the applicability of international radiation therapy guidelines in resource-constrained settings. The prevalence of cervical cancer is 4 times higher in LMICs than in high-income countries (HICs).3 These disparities largely result from inequalities in access to diagnosis and adequate treatment.13 In Morocco, cervical cancer remains a major public health concern, ranking as the second most common cancer among women, with an estimated incidence of approximately 10.4 cases per 100,000 women and a mortality rate of 5.8 per 100,000.14 Importantly, more than 80% of patients are diagnosed at intermediate or advanced stages, reflecting limited access to organized screening programs and early detection strategies.14 This situation highlights the urgent need to improve health care access for women in LMICs to reduce cervical cancer incidence and mortality.15 In contrast, HICs such as France have benefited from long-standing screening strategies and broader access to HPV vaccination, resulting in lower incidence and improved outcomes. In 2017, approximately 2850 new cases of cervical cancer were diagnosed in France, with around 1100 deaths, corresponding to an age-standardized incidence rate of 6.0 per 100,000 women and a mortality rate of 1.7 per 100,000.16 Although incidence and mortality have steadily declined since the 1980s, this decrease has slowed since the early 2000s, likely reflecting limitations in screening coverage and participation.16 The median age at diagnosis is 53 years, highlighting the persistent burden of disease even in high-income settings.16 Histologically, cervical cancer is classified mainly into 2 types: squamous cell carcinomas, which represent approximately 80% of cases, and adenocarcinomas, accounting for about 20%.17,18 Radiation therapy is a cornerstone treatment, especially for advanced stages.19 International guidelines from organizations including the International Federation of Gynecology and Obstetrics (FIGO), the European Society of Gynecological Oncology (ESGO), and the European Society for Radiotherapy and Oncology (ESTRO) are crucial for standardizing clinical radiation therapy practices. In 2018, ESGO, in collaboration with ESTRO and the European Society of Pathology (ESP), identified significant variability in clinical practices worldwide and subsequently published updated evidence-based guidelines for cervical cancer management.4 Although international radiation therapy guidelines for cervical cancer are well established and supported by strong evidence, their implementation varies considerably across countries. LMICs often face particular challenges that may limit guideline adherence and treatment effectiveness.20 The objective of our study is to evaluate the implementation of international radiation therapy guidelines for cervical cancer in Morocco and France, representing LMICs and HICs health care settings, respectively, according to the World Bank classification.21 Despite their geographic proximity and long-standing academic and scientific collaborations in oncology, including joint research initiatives and publications involving Moroccan and French investigators,12,22,23 Morocco and France differ substantially in terms of health care system organization, access to radiation therapy technologies, and implementation of cervical cancer prevention strategies, although Morocco has experienced major developments in treatment facilities, particularly in radiation therapy, over the past 3 decades. This contrast provides a relevant framework to assess the real-world applicability of international radiation therapy guidelines across 2 distinct resource settings. Our survey, designed for specialists involved in cervical cancer management, through a dedicated questionnaire, aimed to (1) explore daily radiation therapy practice, (2) identify factors influencing barriers to optimal radiation therapy delivery, and (3) ensure applicability and/or necessity of adaptations to implement Western radiation therapy guidelines in an LMIC such as Morocco. Methods and Materials Target population This was a cross-sectional observational study based on an electronic survey. The questionnaire was developed and validated through an expert panel review (content validity assessment) involving international specialists in radiation oncology and gynecologic oncology. The experts evaluated the clarity, relevance, and clinical appropriateness of the items, and their feedback was incorporated into the final version of the questionnaire. The questionnaire was disseminated electronically through professional networks, including scientific societies, academic collaborations, and informal contacts. The survey targeted physicians directly involved in cervical cancer management, primarily radiation oncologists, as well as gynecologic oncologists and medical oncologists participating in multidisciplinary tumor boards and treatment decision-making. This approach was chosen to align with the primary objective of the study, which was to assess clinical decision-making, adherence to radiation therapy-related guidelines, and access to advanced diagnostic and therapeutic modalities. These aspects are primarily determined at the specialist level, especially in relation to treatment planning, imaging strategies, and brachytherapy practices. Although cervical cancer care is inherently multidisciplinary, the inclusion of specialists ensured a more consistent evaluation of guideline implementation across settings with different resource levels. The questionnaire was developed by a multidisciplinary panel of 11 international experts in radiation oncology and gynecologic oncology. Among them, 3 experts were from France, and 8 experts were from Morocco, ensuring balanced representation of different health care systems. All experts had specific experience in cervical cancer management and/or radiation therapy practice. Participants had between 8 and 30 years of professional experience, ensuring representation of both early-career and senior specialists. The questionnaire was also pilot-tested for clarity, consistency, and feasibility before dissemination. Questionnaire content and data collection Data were collected via a structured questionnaire validated by a mix of international experts from LMICs and HICs and distributed electronically. The questionnaire, designed to ensure relevance and clarity, covered various quantitative variables. A nonprobabilistic convenience sampling method was used to recruit participants due to its practicality for this study. The questionnaire development process followed a stepwise approach, including expert consensus, literature review, and mapping of items to international cervical cancer radiation therapy guidelines, particularly ESGO/ESTRO/ESP 2023. Variables were operationalized according to predefined clinical domains, including imaging, external beam radiation therapy, brachytherapy, and treatment planning parameters. The questionnaire included 7 sections, covering the main aspects of cervical cancer management, relevant to radiation therapy-oriented guideline implementation. Questionnaire items were designed either as general practice-based questions assessing usual clinical decision-making or as structured clinical scenarios, depending on the domain evaluated, in order to standardize the interpretation of respondents’ practices. The first section collected respondents’ demographics and institutional background. This section was included for descriptive purposes and was not considered a core component of treatment evaluation. The second focused on prevention and screening practices, including HPV vaccination. Although prevention is not directly addressed in the ESGO/ESTRO/ESP 2023 recommendations evaluated in this study, these items were included to reflect the WHO Cervical Cancer Elimination Initiative framework and to capture key components of the cervical cancer care continuum that may influence the implementation of guideline-based management. Additional screening strategies included cytology and HPV testing, where applicable. The third addressed diagnostic and staging procedures, such as MRI and positron emission tomography-computed tomography (PET-CT) usage. The fourth explored therapeutic strategies according to FIGO stage, including surgery, chemoradiation therapy, and brachytherapy. The fifth section evaluated external beam radiation therapy practices, including intensity modulated radiation therapy (IMRT)/image-guided radiation therapy (IGRT) use, treatment timing, and adherence to guidelines. The sixth section covered brachytherapy practices, including treatment timing, imaging guidance, anesthesia, fractionation, and dosimetric planning. The final section of the questionnaire assessed multiple barriers to the implementation of advanced radiation therapy techniques, including access to equipment, availability of imaging modalities, training level of staff, and institutional constraints. The questionnaire was distributed between mid-June and early September, and responses were collected during the same period. The survey was administered using an online platform (Google Forms/institutional electronic survey system), ensuring standardized data collection. Participation was voluntary and anonymous, and no personal identifiers were collected to ensure confidentiality. A total of 150 questionnaires were distributed, with 77 responses received, resulting in a response rate of 51.3%. All completed questionnaires were included in the final analysis without exclusion. Where applicable, multiple international guidelines were used as references for questionnaire construction, including ESGO/ESTRO/ESP 2023 guidelines, EMBRACE II recommendations, and relevant radiation therapy consensus statements. Each section of the questionnaire was mapped to specific guideline domains to ensure methodological alignment. No missing data were recorded, as all submitted questionnaires were fully completed and included in the final analysis. Analyses Given the exploratory nature of this cross-sectional survey and the primary objective of describing real-world patterns of practice rather than testing predefined hypotheses, a descriptive statistical approach was chosen. Categorical variables were summarized as frequencies and percentages, allowing comparison of practice patterns between the 2 settings. No formal inferential testing (eg, chi-square tests) was performed, as the study was not powered for hypothesis testing and aimed to generate hypothesis-forming insights rather than confirmatory conclusions. This approach is consistent with similar practice pattern surveys in oncology literature. All responses were based on respondents’ reported routine clinical practice, reflecting a “typical patient scenario” rather than individual patient-level data. Results Characteristics of the participants The study included a total of 77 participants, with 45 respondents from Morocco and 32 from France. Participants were predominantly female (64.9%), with males representing 35.1%. The most represented age group was 40 to 49 years, accounting for 44.2% of participants. In terms of practice, 31.6% of respondents were specialists working in the public sector, while another 31.6% practiced in the private sector (Table 1).Table 1Demographic and professional characteristics of study participants stratified by countryTable 1 dummy alt textVariableTotal (n = 77)France (n = 32)Morocco (n = 45)Female, n (%)50 (64.9%)19 (59.4)31 (68.9)Male, n (%)27 (35.1%)13 (40.6)14 (31.1)Age 40-49 y, n (%)34 (44.2%)14 (43.7)20 (44.4)Practice setting—public, n (%)24 (31.6%)11 (34.4)13 (28.9)Practice setting—private, n (%)24 (31.6%)12 (37.5)12 (26.7) Table 1Demographic and professional characteristics of study participants stratified by countryTable 1 dummy alt textVariableTotal (n = 77)France (n = 32)Morocco (n = 45)Female, n (%)50 (64.9%)19 (59.4)31 (68.9)Male, n (%)27 (35.1%)13 (40.6)14 (31.1)Age 40-49 y, n (%)34 (44.2%)14 (43.7)20 (44.4)Practice setting—public, n (%)24 (31.6%)11 (34.4)13 (28.9)Practice setting—private, n (%)24 (31.6%)12 (37.5)12 (26.7) Demographic and professional characteristics of study participants stratified by country HPV vaccination Regarding vaccination practices, 86.8% of respondents reported that, in their routine clinical practice, the majority of patients do not receive HPV vaccination. Regarding screening practices, 61.8% of respondents reported that, in their routine clinical practice, most patients do not regularly participate in screening programs, whereas 31.6% reported regular participation. Diagnosis, imaging, and staging For diagnosis and staging, MRI was systematically performed in 98.7% of specialists involved in cervical cancer management; However, 38.4% of MRIs were limited to pelvic imaging without lumbar-aortic sections. To assess the lumbar-aortic region, 70.4% of respondents recommended PET-CT as an alternative. In France, 18F-FDG PET-CT was widely used for para-aortic staging, with 97% of respondents reporting routine use, while only 3% reported relying on conventional abdominal CT. In Morocco, PET-CT was less frequently used, with 59% of respondents reporting routine use, whereas 41% reported relying on abdominal CT. Treatment For FIGO stages IB1 and IB2, therapeutic approaches varied between countries. In France, 28% of respondents favored surgery compared with 34% in Morocco. Preoperative brachytherapy was chosen by 16% of respondents in France and 34% in Morocco. Combined radiation therapy and brachytherapy was preferred by 16% of respondents in France and 18% in Morocco (Fig. 1).Figure 1Therapeutic practices for IB1 and IB2 stages of cervical cancer in France and 121 Morocco.Figure 1 dummy alt text Therapeutic practices for IB1 and IB2 stages of cervical cancer in France and 121 Morocco. External beam radiation therapy In the absence of high-risk prognostic factors (eg, positive surgical margins [R1] or nodal involvement [N+]), 72% of respondents reported recommending adjuvant radiation therapy in patients with intermediate-risk features such as tumor size and lymphovascular space invasion. This recommendation was reported by 77% of respondents in France and 68% in Morocco. According to the 2023 ESTRO/ESGO criteria, practices in both countries were broadly similar. In both settings, concurrent chemoradiation therapy followed by brachytherapy was reported as the standard of care for locally advanced cervical cancer, with weekly cisplatin at 40 mg/m² (Table 2). Image-guided brachytherapy (CT- or MRI-based) was reported as routinely used by respondents in both countries.Table 2Comparison between France and Morocco regarding compliance with ESTRO/ESGO criteriaTable 2 dummy alt textESTRO/ESGO 2023 criteriaFrance (n = 32)Morocco (n = 45)MRI + clinical exam ≥ 90%32 (100%)45 (100%)FDG PET scan ≥ 90% of cases32 (100%)36 (80%)Maximum of 6 wk between diagnosis and treatment32 (100%)41 (90%)Patients treated with RCC + brachytherapy for locally advanced stages ≥ 95%32 (100%)45 (100%)IMRT > 95%32 (100%)Post-op: 25 (55%); immediately: 20 (45%)Daily OBI IGRT considering ITV ≥ 95%23 (72%)24 (53%)SIB for ADP boost27 (85%)9 (21%)Weekly cisplatin chemotherapy 40 mg/m²32 (100%)45 (100%)Image-guided brachytherapy with CT or MRI 100%32 (100%)45 (100%)MRI before the first application ≥ 60%29 (90%)11 (25%)Combined application for asymmetric volumes ≥ 40%20 (64%)4 (9%)OTT < 50 d ≥ 90%24 (76%)24 (53%)Number of patients >10/y26 (82%)32 (72%)Abbreviations: ADP = adenopathy; CT = computed tomography; ESTRO = European Society for Radiotherapy and Oncology; ESGO = European Society of Gynecological Oncology; FDG PET = fluorodeoxyglucose positron emission tomography; IGRT = image-guided radiation therapy; IMRT = intensity modulated radiation therapy; ITV = internal target volume; MRI = magnetic resonance imaging; OBI = on-board imaging; OTT = overall treatment time; RCC = radiochemotherapy; SIB = simultaneous integrated boost. Table 2Comparison between France and Morocco regarding compliance with ESTRO/ESGO criteriaTable 2 dummy alt textESTRO/ESGO 2023 criteriaFrance (n = 32)Morocco (n = 45)MRI + clinical exam ≥ 90%32 (100%)45 (100%)FDG PET scan ≥ 90% of cases32 (100%)36 (80%)Maximum of 6 wk between diagnosis and treatment32 (100%)41 (90%)Patients treated with RCC + brachytherapy for locally advanced stages ≥ 95%32 (100%)45 (100%)IMRT > 95%32 (100%)Post-op: 25 (55%); immediately: 20 (45%)Daily OBI IGRT considering ITV ≥ 95%23 (72%)24 (53%)SIB for ADP boost27 (85%)9 (21%)Weekly cisplatin chemotherapy 40 mg/m²32 (100%)45 (100%)Image-guided brachytherapy with CT or MRI 100%32 (100%)45 (100%)MRI before the first application ≥ 60%29 (90%)11 (25%)Combined application for asymmetric volumes ≥ 40%20 (64%)4 (9%)OTT < 50 d ≥ 90%24 (76%)24 (53%)Number of patients >10/y26 (82%)32 (72%)Abbreviations: ADP = adenopathy; CT = computed tomography; ESTRO = European Society for Radiotherapy and Oncology; ESGO = European Society of Gynecological Oncology; FDG PET = fluorodeoxyglucose positron emission tomography; IGRT = image-guided radiation therapy; IMRT = intensity modulated radiation therapy; ITV = internal target volume; MRI = magnetic resonance imaging; OBI = on-board imaging; OTT = overall treatment time; RCC = radiochemotherapy; SIB = simultaneous integrated boost. Comparison between France and Morocco regarding compliance with ESTRO/ESGO criteria Abbreviations: ADP = adenopathy; CT = computed tomography; ESTRO = European Society for Radiotherapy and Oncology; ESGO = European Society of Gynecological Oncology; FDG PET = fluorodeoxyglucose positron emission tomography; IGRT = image-guided radiation therapy; IMRT = intensity modulated radiation therapy; ITV = internal target volume; MRI = magnetic resonance imaging; OBI = on-board imaging; OTT = overall treatment time; RCC = radiochemotherapy; SIB = simultaneous integrated boost. The use of IMRT in the postoperative setting reaches 100% in France, while it is declared by only 55% of respondents in Morocco. Similar disparities are observed for IGRT: advanced daily Cone-Beam Computed Tomography -based workflows and online image-guided approaches are more frequently employed in France, whereas in Morocco, basic IGRT protocols and offline verification strategies consistent with International Multicentre Study on MRI-Guided Brachytherapy in Locally Advanced Cervical Cancer (EMBRACE) recommendations remain the most common. The combination of intracavitary and interstitial applications is practiced in 64% of cases in France, compared with only 9% in Morocco (Table 2). Finally, regarding treatment goals, 76% of respondents in France meet an overall treatment time of less than 50 days, versus 53% in Morocco. In terms of patient volume, 82% of respondents in France and 72% in Morocco treat 10 or more patients per year (Table 2). Among Moroccan respondents who do not use IMRT, multiple barriers were reported, including limited accessibility to equipment, lack of dedicated infrastructure, reimbursement-related limitations, and constraints related to training and staffing. Some respondents specifically reported that the financial difference between 3D conformal radiation therapy and IMRT is not fully covered by insurance systems, potentially limiting wider implementation of IMRT in routine practice. Accessibility remained the most frequently reported barrier (72%). IMRT techniques, VMAT is the most frequently used: 87% of Moroccan and 81% of French respondents report its use. Brachytherapy Treatment timing and guidance The interval between brachytherapy and external beam radiation therapy was less than 2 weeks for most respondents (97% in France vs 86% in Morocco). Ultrasound guidance differed between countries: in France, 72% used a combined suprapubic and transrectal approach, whereas in Morocco, 36% used suprapubic guidance only. Regarding anesthesia, general anesthesia was preferred in France, while Morocco reported a combination of general anesthesia, sedation, and spinal anesthesia. MRI was performed before the first brachytherapy application in 90% of cases in France versus 25% in Morocco, and MRI with applicators in place was systematically used in France but not consistently in Morocco. Fractionation, dose, and sources Regarding fractionation, 82% of French practitioners delivered 3 to 4 fractions and 18% delivered more than 4, whereas in Morocco, 95% delivered 3 to 4 fractions. For fractions per application, 73% in France and 100% in Morocco administered fewer than 3 fractions per application. The weekly schedule was 2 to 3 fractions in both countries. High-dose-rate (HDR) sources were predominantly Iridium-192 (63% in France, 61% in Morocco), with the remainder Cobalt-60. Noncatheterization of the cervix occurred in less than 1% of patients in France versus less than 10% in Morocco; in such cases, 28% of French practitioners opted for exclusive radiochemotherapy and 22% for stereotactic body radiation therapy boost, compared with 22% and 3% in Morocco, respectively. Parametrial boost (5-10 Gy) was applied in 25% of cases in France versus 89% in Morocco. Most reported a time interval of less than 6 weeks between preoperative brachytherapy and surgery. Dose rate and planning methods Regarding the dose rate used for uterovaginal brachytherapy, 100% of respondents in Morocco utilize the HDR technique. In France, 72% of respondents also favor HDR, while 20% use the pulse dose rate method, and 8% combine both HDR and pulse dose rate techniques. Regarding image-guided brachytherapy, 75% of respondents in France use MRI guidance, whereas 93% in Morocco rely on CT guidance. For dosimetry, 7% of Moroccan respondents utilize the International Commission on Radiation Units (ICRU) point-based method, while the majority adopt a volume-based approach. Combined use of MRI and CT for planning is applied by 8% of the overall cohort, with 13% in France and 7% in Morocco. Access issues to image-guided brachytherapy were reported by 70% of respondents. Compliance with radiation therapy constraints criteria In France, most radiation therapy criteria for cervical cancer are met, with variable results in Morocco. D90 high-risk clinical target volume was adequate in 90% (France) versus 78% (Morocco), and D98 targets reached in ∼78% of cases in both. The median (EQD2) delivered was 65 to 70 Gy, corresponding to the typical schedules used in each country. Organ at risk (OAR) constraints were respected in both countries, but rectovaginal and parametrial irradiation boost system criteria showed lower compliance in Morocco. Total reference air kerma >2 cGy was achieved in 24% (France) versus 6% (Morocco). Additional practices In France, 56% of practitioners perform ovarian transposition, compared with 41% in Morocco. The use of MRI-compatible applicators is reported at 44% in France and 22% in Morocco (Table 4). Regarding vaginal applicator types, France predominantly uses ovoid, ring, and cylinder applicators, whereas in Morocco, the ovoid applicator is the most commonly employed.Table 3Comparison of compliance with ESTRO/ESGO 2023 radiation therapy criteria between France and Morocco for cervical cancer treatmentTable 3 dummy alt textESTRO/ESGO 2023 criteriaFrance (n = 32)Morocco (n = 45)D90 HR-CTV > 85 Gy32 (100%)35 (78%)D90 IR-CTV > 60 Gy32 (100%)35 (78%)D98 CTV HR > 80 Gy/CTV IR > 60 Gy/GTV > 90 Gy25 (79%)35 (77%)Combined point A3 (9%)8 (17%)Point A alone0 (0%)10 (22%)D2cc bladder <85 Gy, rectum and sigmoid <75 Gy and/or ICRU bladder point <75 Gy32 (100%)45 (100%)Rectovaginal point <75 Gy20 (62%)17 (38%)Isodose 140 Gy + lateral vaginal point (PIBS ± 2 cm)12 (37%)9 (19%)TRAK ratio8 (24%)3 (6%)Abbreviations: D90/D98 = dose covering 90%/98% of the volume; ESTRO = European Society for Radiotherapy and Oncology; ESGO = European Society of Gynecological Oncology; GTV = gross tumor volume; D2cc: The dose received by the most exposed 2 cm³ of an organ at risk. HR-CTV = high-risk clinical target volume; ICRU = International Commission on Radiation Units; IR-CTV = intermediate-risk clinical target volume; PIBS = parametrial irradiation boost system; TRAK = total reference air kerma.Table 4Comparison of brachytherapy and radiation therapy practices in France and MoroccoTable 4 dummy alt textITEMFrance (n = 32)Morocco (n = 45)Ovarian transposition18 (56%)18 (41%)MRI-compatible applicator14 (44%)10 (22%)Type of vaginal applicatorOvoid–ring–cylinderPredominant use of ovoid applicatorsDelay between brachytherapy and external RT (<2 wk)31 (97%)39 (86%)Ultrasound guidance23 (72%) suprapubic + transrectal16 (36%) suprapubicAnesthesiaGeneral anesthesiaGA/sedation/spinal anesthesiaNumber of fractions3-4: 26 (82%); >4: 6 (18%)3-4: 43 (95%)Fractions per application (<3)23 (73%)45 (100%)Fractions per week2-3 per week (100%)2-3 per week (100%)HDR sourceIr-192: 20 (63%); Co-60: 12 (37%)Ir-192: 27 (61%); Co-60: 18 (39%)Noncatheterization of cervix<1/100 (∼0-1 case)<1/100 (∼0-1 case)Management of noncatheterizationRCC: 9 (28%); SBRT boost: 7 (22%)RCC: 10 (22%); SBRT boost: 1 (3%)Parametrial boost (5-10 Gy)8 (25%)40 (89%)Abbreviations: HDR = high dose rate; MRI = magnetic resonance imaging; RCC = radiochemotherapy; RT = radiation therapy; SBRT = stereotactic body radiation therapy. Table 3Comparison of compliance with ESTRO/ESGO 2023 radiation therapy criteria between France and Morocco for cervical cancer treatmentTable 3 dummy alt textESTRO/ESGO 2023 criteriaFrance (n = 32)Morocco (n = 45)D90 HR-CTV > 85 Gy32 (100%)35 (78%)D90 IR-CTV > 60 Gy32 (100%)35 (78%)D98 CTV HR > 80 Gy/CTV IR > 60 Gy/GTV > 90 Gy25 (79%)35 (77%)Combined point A3 (9%)8 (17%)Point A alone0 (0%)10 (22%)D2cc bladder <85 Gy, rectum and sigmoid <75 Gy and/or ICRU bladder point <75 Gy32 (100%)45 (100%)Rectovaginal point <75 Gy20 (62%)17 (38%)Isodose 140 Gy + lateral vaginal point (PIBS ± 2 cm)12 (37%)9 (19%)TRAK ratio8 (24%)3 (6%)Abbreviations: D90/D98 = dose covering 90%/98% of the volume; ESTRO = European Society for Radiotherapy and Oncology; ESGO = European Society of Gynecological Oncology; GTV = gross tumor volume; D2cc: The dose received by the most exposed 2 cm³ of an organ at risk. HR-CTV = high-risk clinical target volume; ICRU = International Commission on Radiation Units; IR-CTV = intermediate-risk clinical target volume; PIBS = parametrial irradiation boost system; TRAK = total reference air kerma. Comparison of compliance with ESTRO/ESGO 2023 radiation therapy criteria between France and Morocco for cervical cancer treatment Abbreviations: D90/D98 = dose covering 90%/98% of the volume; ESTRO = European Society for Radiotherapy and Oncology; ESGO = European Society of Gynecological Oncology; GTV = gross tumor volume; D2cc: The dose received by the most exposed 2 cm³ of an organ at risk. HR-CTV = high-risk clinical target volume; ICRU = International Commission on Radiation Units; IR-CTV = intermediate-risk clinical target volume; PIBS = parametrial irradiation boost system; TRAK = total reference air kerma. Table 4Comparison of brachytherapy and radiation therapy practices in France and MoroccoTable 4 dummy alt textITEMFrance (n = 32)Morocco (n = 45)Ovarian transposition18 (56%)18 (41%)MRI-compatible applicator14 (44%)10 (22%)Type of vaginal applicatorOvoid–ring–cylinderPredominant use of ovoid applicatorsDelay between brachytherapy and external RT (<2 wk)31 (97%)39 (86%)Ultrasound guidance23 (72%) suprapubic + transrectal16 (36%) suprapubicAnesthesiaGeneral anesthesiaGA/sedation/spinal anesthesiaNumber of fractions3-4: 26 (82%); >4: 6 (18%)3-4: 43 (95%)Fractions per application (<3)23 (73%)45 (100%)Fractions per week2-3 per week (100%)2-3 per week (100%)HDR sourceIr-192: 20 (63%); Co-60: 12 (37%)Ir-192: 27 (61%); Co-60: 18 (39%)Noncatheterization of cervix<1/100 (∼0-1 case)<1/100 (∼0-1 case)Management of noncatheterizationRCC: 9 (28%); SBRT boost: 7 (22%)RCC: 10 (22%); SBRT boost: 1 (3%)Parametrial boost (5-10 Gy)8 (25%)40 (89%)Abbreviations: HDR = high dose rate; MRI = magnetic resonance imaging; RCC = radiochemotherapy; RT = radiation therapy; SBRT = stereotactic body radiation therapy. Comparison of brachytherapy and radiation therapy practices in France and Morocco Abbreviations: HDR = high dose rate; MRI = magnetic resonance imaging; RCC = radiochemotherapy; RT = radiation therapy; SBRT = stereotactic body radiation therapy. Discussion General disparities in health care systems Disparities in health care systems between HICs and low‑ to LMICs significantly affect cancer survival outcomes, as inequities in access to diagnostics, treatment, and prevention translate into poorer overall prognosis.24 Prevention remains critically underutilized in many LMICs, where systemic limitations in vaccine delivery and inequities in access to preventive services contribute to increased morbidity and mortality from otherwise preventable diseases.25 These findings are consistent with global efforts aimed at reducing cervical cancer burden through improved access to prevention, early detection, and treatment services. Our results, therefore, reflect the real-world challenges in achieving equitable health care delivery, particularly in resource-limited settings. Prevention and screening Our survey revealed a notably low HPV vaccination coverage in both France and Morocco, underscoring a major issue in the primary prevention of cervical cancer. This finding aligns with global trends where many LMICs lack national HPV vaccination programs.26 These countries exhibit the highest cervical cancer incidence and mortality rates, making vaccination coverage critical. In the present study, the screening rates remain insufficient as well, with over 60% of respondents reporting irregular participation of patients in screening programs. HPV screening, a cornerstone of cervical cancer prevention, remains unevenly accessible worldwide, especially in LMICs.27 While Morocco still faces these challenges, the introduction of a national cancer plan marked significant progress in screening, notably for cervical cancer. Since 2010, a national early detection program has covered nearly all Moroccan regions,28 featuring free screening, referral centers, mobile teams for remote areas, and a structured national framework. Morocco aims to strengthen and expand this program to reach 70% participation.29 France targets a similar 70% screening coverage, complemented by an ambitious vaccination strategy aiming for 80% HPV vaccine coverage by 2030. Vaccination, free and universal from age 11, forms part of an integrated prevention policy.30 Epidemiological and system-level disparities (France vs Morocco) Beyond individual practice variations, the differences observed between France and Morocco in our study reflect broader systemic and epidemiological disparities between the 2 health care settings. France and Morocco were selected as representative HICs and LMICs of the Mediterranean region, given their geographic proximity and long-standing academic and clinical collaborations, but marked differences in health care infrastructure, cancer control strategies, and radiation therapy resources. These structural disparities are also reflected in cervical cancer epidemiology, with Morocco continuing to report a higher incidence and a greater proportion of locally advanced disease, while France benefits from organized screening programs and HPV vaccination policies associated with earlier diagnosis and reduced disease burden. Diagnosis and imaging access Accurate staging is critical in guiding cervical cancer treatment and prognosis. In many LMICs, the high incidence of locally advanced disease contrasts sharply with limited access to advanced imaging modalities (MRI, CT, PET-CT), which are routinely available in HICs.31,32 The 2018 FIGO staging update incorporated imaging findings to replace the previous clinically based 2009 system.33 Although MRI is broadly included in management protocols, disparities remain in access to comprehensive multiparametric MRI for Moroccan patients.34 Limitations in MRI access are due to equipment availability, exam costs, and specialized imaging center density. In contrast, French access to high-resolution MRI combined with standardized protocols allows more complete staging per ESGO guidelines. The Lancet Oncology Commission report on medical imaging and nuclear medicine, based on data from 211 countries via the IAEA’s IMAGINE database, highlights stark disparities between HICs and LMICs in imaging capacity.35 Among the most affected modalities is 18F-FDG PET-CT, whose access remains severely limited in LMICs. In Africa, only a few countries (Egypt, South Africa, Morocco, Algeria, Tunisia, Kenya) have cyclotrons for radiotracer production.35 In the broader context of LMICs, access to MRI remains highly heterogeneous. While many LMICs report limited or intermittent availability of MRI for cervical cancer staging, particularly in sub-Saharan Africa and parts of South Asia, Morocco demonstrates relatively higher access compared with lower-resourced settings, supported by recent investments in oncology infrastructure and imaging platforms.36,37 This makes Morocco a relevant reference setting for understanding the gradual transition toward guideline-concordant imaging strategies in resource-constrained environments, particularly in comparison with both lower-resource LMICs and HICs such as France. In our study, the use of PET-CT for para-aortic staging differs notably between France (97%) and Morocco (59%). These gaps reflect access disparities rather than divergent clinical choices. Although the EMBRACE II protocol recommends PET-CT for initial staging, it is not mandatory, recognizing infrastructure variability.38 Moroccan practitioners adapt diagnostic strategies accordingly, relying on alternative exams such as thoraco-abdomino-pelvic CT or MRI, while adhering to international guideline principles. Therapeutic approaches and radiation therapy implementation Heterogeneity in therapeutic approaches for FIGO 2018 stages IB1 and IB2 cervical cancer reflects underlying challenges in accurate staging and resource availability, particularly in LMICs, where limited access to advanced imaging and diagnostic modalities contributes to variability in clinical management.39 In our study, therapeutically, management of FIGO 2018 stages IB1 and IB2 shows varied approaches between France and Morocco. However, FIGO IB1 and IB2 stages encompass heterogeneous clinical presentations with differences in tumor size, lymphovascular invasion, and other prognostic factors that may influence treatment decisions. Consequently, the variability observed in therapeutic approaches may partly reflect differences in case-mix rather than discrepancies in guideline implementation alone, as previously reported in the literature.33,39 We acknowledge this limitation and clarify that the aim of this comparison was not to establish differences in therapeutic superiority between stages, but rather to describe real-world variations in treatment patterns and assess the level of adherence to international guidelines across 2 different health care settings. Surgery is commonly employed in both countries (34% Morocco, 28% France). Preoperative brachytherapy, more frequent in Morocco (34% vs 16%), aims to optimize surgical outcomes. A recent systematic review associated this approach with reduced positive margins, improved pathological response, and better 5-year overall survival.40 French data show excellent oncological outcomes with favorable survival and low complication rates.41 HDR brachytherapy is predominantly used in both countries (83.8%), fully consistent with recent ESGO/ESTRO/ESP (2023), American Brachytherapy Society (AAPM) (2023), and American Brachytherapy Society (ABS) guidelines, which endorse HDR-B as the reference modality for cervical cancer treatment.4,42,43 As highlighted by Tumba et al., Africa bears a large share of the global cancer burden but has access to only 5% of cancer care resources, with brachytherapy particularly impacted, over 70% of units are located in just 5 countries, including Morocco.44 Imaging is essential for brachytherapy planning per ESTRO/ESGO guidelines. Our survey found MRI before the first application in 90% of cases in France, while in Morocco, only 25% have an initial MRI, most planning relying on CT, sometimes complemented by MRI without applicators. CT-based planning is supported by studies in resource-limited settings. A meta-analysis of 13 studies found no significant dosimetric differences between MRI-, CT-, and hybrid-based planning,45 with comparable clinical outcomes reported across different setting.46,47 These findings support CT-based brachytherapy planning as a clinically relevant alternative in resource-limited environments. Dosimetry, quality indicators, and adaptation of guidelines In our survey, among Moroccan respondents using IMRT, VMAT was the most frequently reported delivery technique (87%), widely adopted in developed countries due to its dosimetric advantages, is also commonly used in Morocco, reflecting partial alignment with international radiation therapy standards.48,49 Organ-at-risk doses (D2cc bladder, rectum, sigmoid) and ICRU bladder point doses are well controlled in Morocco with 100% compliance, demonstrating treatment safety prioritization. This aligns with a national survey where 39% treated over 20 patients in 2022 with image-guided HDR brachytherapy, largely following Groupe Européen de Curiethérapie–European Society for Radiotherapy and Oncology (GEC-ESTRO) contouring and dose prescription guidelines despite MRI availability in only 6% of cases, a figure consistent with our findings (Table 3).50 Compliance with the rectovaginal point dose limit (<75 Gy) is achieved in only 38% of Moroccan cases versus 62% in France, underscoring ongoing challenges in organ-at-risk dose management, particularly where advanced imaging and volumetric optimization are not yet widespread. The rectovaginal point remains clinically relevant as a dosimetric landmark, with international guidelines setting this threshold to limit rectal and vaginal toxicities.51 Use of point A alone (22%) or combined with other landmarks (17%) is more frequent in Morocco, reflecting a transitional reliance on ICRU point-based normalization. This approach could serve as a useful intermediate step toward volume-based dosimetry, with treatment plan optimization gradually moving from point-based to volumetric methods. Encouraging this transition would support standardized practice in both countries (Table 3). Overall, these data demonstrate that quality dosimetric planning is achievable in LMICs where teams are trained, motivated, and able to adapt guidelines to local realities.52 Technical parameters also reflect organizational and resource differences. Limited access to MRI-compatible applicators in Morocco (22% vs 44% France) hinders image-based plan optimization, though effective CT-guided alternatives exist.52 The recommended interval between external radiation therapy and brachytherapy is generally respected in Morocco (86%) though slightly less than France (97%), potentially modestly impacting tumor control.12 Both countries largely adopt internationally recommended fractionation schemes (3-4 fractions, 2-3 per week), reflecting alignment with guidelines even in resource-constrained contexts. Combined endocavitary and interstitial applications are used in 64% of French cases versus only 9% in Morocco. This gap mainly stems from limited access to commercial applicators designed for hybrid techniques and a lack of training for Moroccan medical and paramedical teams in vaginal mold techniques recommended by ESTRO.51 Nonetheless, some Moroccan centers, notably Rabat, have begun implementing hybrid techniques successfully in the local context.53 Our findings are consistent with those reported by Belkacemi et al,22 who highlighted the limited applicability of international oncology guidelines in LMICs, particularly in the Mediterranean region.22 Their analysis emphasizes that optimal management of cervical cancer, as defined by Western protocols, often encounters persistent structural barriers such as limited access to radiation therapy and brachytherapy equipment, insufficient MRI availability, and a shortage of trained specialists involved in cervical cancer management. In Morocco, despite recent improvements, these resource-related constraints continue to affect compliance with quality indicators set by leading international societies such as ESGO and ESTRO.22 Belkacemi et al22 advocate for adapting international standards to local realities and call for implementation strategies that are sensitive to specific regional contexts.22 Study limitations This study has several limitations that should be acknowledged. First, the relatively small sample size and the use of a nonprobabilistic convenience sampling method may limit the generalizability of the findings. Second, the potential for selection bias cannot be excluded, as participants were recruited through professional networks and may represent more engaged or better-resourced practitioners. Third, the study was restricted to medical specialists, which does not reflect the full multidisciplinary nature of cervical cancer care, particularly the role of radiation therapists, nurses, and other health care professionals. In addition, the analysis was purely descriptive and did not include inferential statistical testing, limiting the ability to draw causal inferences or assess the statistical significance of observed differences. Finally, self-reported practices may differ from actual clinical practice, introducing a potential reporting bias. Morocco may represent a relatively advanced LMIC that has achieved important progress in oncology infrastructure and radiation therapy implementation through national cancer control strategies. Nevertheless, persistent disparities in access to MRI, PET-CT, and advanced brachytherapy techniques continue to limit full adherence to international recommendations. Therefore, our findings may provide practical insights for other LMICs facing similar transitional challenges in implementing international radiation therapy guidelines. Conclusion To the best of our knowledge, this is the first published survey that compared the applicability of Western guidelines between 1 HIC and 1 LMIC for cervical cancer management. Our data highlight a satisfactory compliance level of guidelines implementation among Moroccan respondents despite a more constrained resource setting. Moreover, our report underlines the importance of sustained investments in training and national cancer planning to implement international standards of care and adopt Western guidelines in the limited-resource contexts. Thus, improving access to MRI, modern applicators, and standardized ultrasound guidance, along with reducing treatment delays, could further enhance the quality of care to generalize optimal cervical cancer management for all patients in LMICs. Disclosures None.